Germany-based BioNTech (NASDAQ: BNTX) saw its U.S. listed stock enjoy a mini-pop on Wednesday, and for once this wasn't largely based on the Comirnaty COVID-19 vaccine it developed with Pfizer. Rather ...

An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (NASDAQ: BNTX). Investors were concerned about the latest top-level ...

BioNTech (BNTX) stock is down nearly 20% at the time of writing after the German company posted a Q4 loss, issued muted guidance, and said its cofounders will depart by the end of this year CEO Uğur ...

If you are wondering whether BioNTech is starting to look like value after the Covid vaccine boom faded, or if the current ...

Nothing about the recent past, present, or foreseeable future seems all that compelling.

People aiming to get its Comirnaty Covid vaccine won't need a doctor's prescription to do so. This was among several measures being considered by an advisory panel to the CDC. Investors were cheered ...

We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE’s share was trading at $103.80 as of March 4th.

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...

The biotech continues to embrace artificial intelligence (AI) technology, which is heartening for investors. It owns and manages an AI developer, InstaDeep. Showing their approval, those market ...

A new federal government appointment had investors worried about vaccine makers. This was compounded by an analyst's price target cut for the German biotech. The Food and Drug Administration (FDA), a ...